Navigation Links
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Date:12/22/2009

taining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the December 15, 2009 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
2. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
3. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Resverlogix Provides Quarterly Update
7. Resverlogix Board of Directors Update
8. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
9. Resverlogix Announces Closing of Debt Redemption
10. Resverlogix Eliminates Sixty Percent of Remaining Debt
11. Resverlogix Issues a Management Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... Pittsburgh, PA (PRWEB) November 25, 2014 ... release of its official conference and exposition mobile app, ... available for free download in the App Store for ... as a valuable resource tool before, during and after ... guide containing details on exhibiting companies, technical sessions, Conferee ...
(Date:11/26/2014)... SoundConnect , an award winning unified ... that Darren Suders has joined the team as Director ... the partner program through innovative offerings, consistent ... Darren brings more than 10-years of channel telecommunication experience ... operations, from policy development, to partner education and to ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... NOIDA, India, Jan. 21 Jubilant Organosys Ltd,headquartered ... its subsidiary,Jubilant Biosys Ltd., based in Bangalore, has ... will further enable the process of,high throughput screening, ... launched in the US and Europe initially, allows ...
... Germany and STOCKHOLM, January 21 Richter-Helm,BioLogics GmbH ... signed an,agreement for the development and manufacturing of ... athero-thrombosis through binding of the,protein, Annexin A5, to ... the treatment of patients with Acute Coronary Syndrome ...
... AMGN ) today announced that it plans to ... Monday, Jan. 26, 2009 after the close of the financial ... with the investment community at 2:00 p.m. Pacific Time. ... chairman and chief executive officer, and other members of Amgen,s ...
Cached Biology Technology:Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 3Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results 2
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
(Date:11/4/2014)... – A majority of Madagascar,s 101 species of lemurs ... consequences for the rainforests they call home. A new ... lemurs can have on rainforest tree populations, which raises ... on the region,s rich biodiversity. , A large proportion ... lemurs. Lemurs in turn disperse the seeds of ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... could lead to a novel approach to the treatment of ... Health Science Center at Houston report they are the first ... disease (COPD). Findings appear online and will be in the ... the journal of The Federation of American Societies for Experimental ...
... are developing technologies that use lasers to create arterial ... 10 times faster and also less expensively than is ... meet the huge global market for artificial hips and ... and director of Purdue,s Center for Laser-Based Manufacturing. ...
... ADHD, is one of the most common neuropsychiatric ... affected with the disorder. Key symptoms of ADHD ... reduced ability to focus attention. Clinically, three different ... a primarily hyperactive/impulsive subtype, and a combined subtype ...
Cached Biology News:UT scientists discover link between protein and lung disease 2Laser processes promise better artificial joints, arterial stents 2Laser processes promise better artificial joints, arterial stents 3The role of genetic factors in adult ADHD 2The role of genetic factors in adult ADHD 3The role of genetic factors in adult ADHD 4The role of genetic factors in adult ADHD 5The role of genetic factors in adult ADHD 6
... The kit provides a simple and efficient method ... and from PCR mixes. DNA fragments selectively absorbed ... for gel extraction or at room temperature for ... Up to 25 g of DNA can be ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
... Fujifilm Life Science BAS-5000 is the ... Plate equipment. The top member of ... features a superior Imaging Plate (IP) ... in target subjects. Fujifilm BAS-5000 does ...
Biology Products: